Dizhe Medical: The company will announce multiple research outcomes in the field of lung cancer at the 2025 World Lung Cancer Congress.

Dize pharmaceuticals announced that the company presented 11 latest research studies on its independently developed new targeted therapy for lung cancer, Shuwozhe, and the highly selective JAK1 inhibitor Gaoruizhe at the 2025 World Lung Cancer Congress. Among them, the latest research results of the international multicenter registered clinical trial "Wukong 1B" of Shuwozhe were presented orally at the conference. The latest research results of the first international multicenter registered clinical trial "Wukong 1B" of Shuwozhe showed that Shuwozhe as second-line treatment in patients with exon 20 insertion mutations in the epidermal growth factor receptor NSCLC had a favorable benefit/risk ratio. In addition, the overall response rate (ORR) of Shuwozhe combined with anlotinib as first-line treatment in patients with EGFR-sensitive mutations and concurrent mutations in NSCLC was 77.8%, and the disease control rate (DCR) was 100%, offering promising treatment options for clinical practice.